Trial Profile
Immunogenicity and Reactogenicity of a Booster Dose of GlaxoSmithKline Biologicals' GSK2036874A Vaccine in Healthy Toddlers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Hib-DTP-hepatitis B vaccine; Poliovirus vaccine inactivated
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 15 Dec 2010 Actual patient number is 312 according to ClinicalTrials.gov.
- 10 Dec 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 10 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.